Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)

Volume 16, 10 Issues, 2017

Download PDF Flyer

CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.188
5 - Year: 2.599

Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets, 13(1): 120-125.

Author(s): Subramanian Rajagopalan, Shankar J. Chinta and Julie K Andersen.

Affiliation: 8001 Redwood Blvd, Novato, CA 94945, USA.


Previously published data from our laboratory demonstrated that pharmacological inhibition of a family of enzymes known as prolyl hydroxylase domain proteins prevents neurotoxicity associated with the acute 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine intoxication model of Parkinson’s disease in young animals. In this study, we assessed whether prolyl hydroxylase domain inhibition was neuroprotective in an inducible genetic dopaminergic glutathione depletion model previously characterized by our laboratory that more closely recapitulates the age-related and progressive nature of the human disease. Pharmacological prolyl hydroxylase domain inhibition via 3,4-dihydroxybenzoate was found to significantly attenuate hallmark mitochondrial dysfunction and loss of dopaminergic substantia nigral pars compacta neurons associated with this model. These studies further validate the possibility that prolyl hydroxylase domain inhibition may constitute a viable therapy for Parkinson’s disease.


Drug therapy, mitochondrial function, nigrostriatal cell loss, Parkinson’s disease, prolyl hydroxylase domain proteins, transgenic mouse model, age, progressive, chronic.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 1
First Page: 120
Last Page: 125
Page Count: 6
DOI: 10.2174/18715273113126660131
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017Pain Therapeutics

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science